Our Products

---

 ImmLab products are staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, companion animals, and farm animals. ImmLab staphylococcal  vaccines are created by introducing the genome of the staphylococcal  bacteriophage into the staphylococcal cell, resulting in the production  of highly immunogenic vaccine comprised of all staphylococcal proteins  and cell-wall components.  

 The  vaccine is designed for prevention and treatment of human  staphylococcal infections. It is non-toxic, does not generate bacterial  resistance, and is affordable. It will address an urgent and ever  growing need in vulnerable populations, where collectivization occurs  (i.e., the military, hospitals, nursing homes, and schools). A key  target for our technology are S.aureus infected individuals and individuals at increased risk of exposure to and infection by S. aureus strains, including methicillin-resistant strains (MRSA),  vancomycin-intermidiate strains (VISA) and vancomycin-resistant strains  (VRSA). ImmLab technology would have a role for pre-treatment of those  facing elective surgery or any other non-urgent invasive treatment. 

 The  vaccine will prevent dairy-cow mastitis caused by the staphylococcus.  The enormous economic impact of this one disease to the American dairy  farmer and, subsequently, to the consumer is well established. Current  therapies (antibiotics, vaccines, management practices) are not  sufficiently effective. Vaccination with this product before infection  will create herd immunity, saving millions of dollars annually to this  industry. 

In the U.S.A. the S. aureus mastitis comprise a total of 10-12% of  all clinical mastitis. It creates the yearly cost/loss of the $2 billion  to the American dairy industry. Longitudinal studies of clinical  mastitis caused by S. aureus detected in the milk of dairy cattle  worldwide was 26% contaminated milk in Tanzania to 23% at Netherland as  of the year 2000. Therefore we are facing the global problem. The  worldwide number of dairy cows as of the year 2003 was more then 238  million. Another dairy animal, which is suffering with the same S.  aureus mastitis problem, is the water buffalo. At the year of 2005 it  was 130 million water buffalos living world wide, more then 60% of the  animals in the Pakistan and India. 

 The  vaccine can treat and prevent the most common skin infections in  companion and farm animals. These infections are caused by the  staphylococcus. The animal contact leads to human colonization,  infection and further spread. Therefore, the use of this vaccine will  affect both veterinary and human medicine. 

 The MRSA is emerging on the companion animals (dogs, cats and  horses) as well as on swine herds through the whole word. The isolated  MRSA strains are identical with the human MRSA strains. This problem,  including a new MRSA strain ST 398 originally isolated from the swine  herds and already isolated on the horses and human including  kindergarten children, is representing another emerging challenge to the  human and animal health.